ERAS
Price
$1.50
Change
-$0.00 (-0.00%)
Updated
Jul 21, 04:59 PM (EDT)
Capitalization
424.93M
17 days until earnings call
KZR
Price
$4.33
Change
-$0.02 (-0.46%)
Updated
Jul 21, 04:59 PM (EDT)
Capitalization
31.78M
Interact to see
Advertisement

ERAS vs KZR

Header iconERAS vs KZR Comparison
Open Charts ERAS vs KZRBanner chart's image
Erasca
Price$1.50
Change-$0.00 (-0.00%)
Volume$11.05K
Capitalization424.93M
Kezar Life Sciences
Price$4.33
Change-$0.02 (-0.46%)
Volume$1.9K
Capitalization31.78M
ERAS vs KZR Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KZR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. KZR commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and KZR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (ERAS: $1.50 vs. KZR: $4.35)
Brand notoriety: ERAS and KZR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 55% vs. KZR: 154%
Market capitalization -- ERAS: $424.93M vs. KZR: $31.78M
ERAS [@Biotechnology] is valued at $424.93M. KZR’s [@Biotechnology] market capitalization is $31.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileKZR’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • KZR’s FA Score: 1 green, 4 red.
According to our system of comparison, both ERAS and KZR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while KZR’s TA Score has 2 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 2 bearish.
  • KZR’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than KZR.

Price Growth

ERAS (@Biotechnology) experienced а +3.45% price change this week, while KZR (@Biotechnology) price change was -3.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.21%. For the same industry, the average monthly price growth was +15.57%, and the average quarterly price growth was +33.92%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+2.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($425M) has a higher market cap than KZR($31.8M). KZR YTD gains are higher at: -35.268 vs. ERAS (-40.239). KZR has higher annual earnings (EBITDA): -76.06M vs. ERAS (-150.24M). ERAS has more cash in the bank: 305M vs. KZR (114M). KZR has less debt than ERAS: KZR (14.1M) vs ERAS (50.8M). ERAS (0) and KZR (0) have equivalent revenues.
ERASKZRERAS / KZR
Capitalization425M31.8M1,336%
EBITDA-150.24M-76.06M198%
Gain YTD-40.239-35.268114%
P/E RatioN/AN/A-
Revenue00-
Total Cash305M114M268%
Total Debt50.8M14.1M360%
FUNDAMENTALS RATINGS
KZR: Fundamental Ratings
KZR
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASKZR
RSI
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 7 days ago
74%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KZR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NMTC0.850.10
+12.92%
NeuroOne Medical Technologies Corp
NFG89.171.14
+1.30%
National Fuel Gas Co
AON356.111.48
+0.42%
Aon plc
ZIP4.66-0.02
-0.43%
ZipRecruiter
OABI1.95-0.01
-0.51%
OmniAb

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+0.67%
RVMD - ERAS
54%
Loosely correlated
-1.92%
XNCR - ERAS
54%
Loosely correlated
-1.10%
OCUL - ERAS
53%
Loosely correlated
-0.44%
BEAM - ERAS
53%
Loosely correlated
+1.47%
ACLX - ERAS
52%
Loosely correlated
-4.74%
More

KZR and

Correlation & Price change

A.I.dvisor indicates that over the last year, KZR has been loosely correlated with CTMX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if KZR jumps, then CTMX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KZR
1D Price
Change %
KZR100%
-2.47%
CTMX - KZR
34%
Loosely correlated
+0.21%
GLTO - KZR
32%
Poorly correlated
-1.73%
IGC - KZR
30%
Poorly correlated
+5.87%
ERAS - KZR
30%
Poorly correlated
+0.67%
FULC - KZR
30%
Poorly correlated
-3.65%
More